PLUS THERAPEUTICS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PLUS THERAPEUTICS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.21M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $5.82M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.91M | Mar 31, 2025 |
| FY2017 | Dec 31, 2017 | $662.0K | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | $467.0K | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | $969.0K | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | $591.0K | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $1.47M | Mar 9, 2018 |
| FY2017 | Sep 30, 2016 | $731.0K | Mar 9, 2018 |
| FY2017 | Jun 30, 2016 | $1.13M | Mar 9, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.67M | Mar 29, 2019 |
| FY2018 | Dec 31, 2017 | $2.69M | Mar 29, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $29.0K | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | ($20.0K) | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | $262.0K | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | ($125.0K) | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $521.0K | Mar 9, 2018 |
| FY2017 | Sep 30, 2016 | $113.0K | Mar 9, 2018 |
| FY2017 | Jun 30, 2016 | $541.0K | Mar 9, 2018 |
| FY2017 | Mar 31, 2016 | $766.0K | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $765.0K | Mar 24, 2017 |
| FY2016 | Sep 30, 2015 | $264.0K | Mar 24, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.39M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($12.98M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($13.32M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($20.28M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($13.40M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($8.24M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($10.89M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | ($12.63M) | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | ($4.29M) | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | ($4.81M) | Mar 9, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.30M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($14.70M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($13.32M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.71M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($12.49M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($9.58M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($3.66M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | ($8.76M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($20.68M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($19.71M) | Mar 9, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.38M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.58M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $9.69M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.70M | Mar 5, 2024 |
| FY2020 | Dec 31, 2020 | $2.70M | Feb 22, 2021 |
| FY2020 | Dec 31, 2019 | $5.37M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $5.52M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.68M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $16.20M | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $19.00M | Mar 24, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.78M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($10.55M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($12.85M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.97M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($10.28M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($8.43M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($5.91M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | ($11.98M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($18.13M) | Mar 29, 2019 |
| FY2013 | Dec 31, 2013 | ($34.56M) | Mar 14, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $146.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $160.0K | Mar 31, 2025 |
| FY2019 | Dec 31, 2019 | $67.0K | Mar 30, 2020 |
| FY2019 | Dec 31, 2018 | $133.0K | Mar 30, 2020 |
| FY2017 | Dec 31, 2017 | $295.0K | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | $67.0K | Mar 9, 2018 |
| FY2016 | Dec 31, 2015 | $611.0K | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | $764.0K | Mar 11, 2016 |
| FY2015 | Dec 31, 2013 | $519.0K | Mar 11, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.33M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.63M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $11.39M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $23.87M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $21.98M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $12.11M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $23.23M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $23.99M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $31.62M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $34.61M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.33M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $15.58M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $12.74M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $17.42M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $11.15M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $9.07M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $22.07M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $18.77M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $18.62M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $23.62M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($8.95M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | ($1.35M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $6.45M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $10.84M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | $3.03M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.16M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $5.23M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $13.00M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $10.99M | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $372.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $372.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $372.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $372.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $372.0K | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $372.0K | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $372.0K | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $372.0K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $3.92M | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $3.92M | Mar 29, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($515.87M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($493.48M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($480.50M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($467.19M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($446.91M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($433.51M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($425.27M) | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | ($414.38M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($401.75M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($379.06M) | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.26M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $76.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $8.55M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.12M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $18.40M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $8.35M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $17.55M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $5.26M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $9.55M | Mar 29, 2019 |
| FY2018 | Dec 31, 2016 | $12.60M | Mar 29, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (11) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Feb 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (11) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Feb 23, 2023 |
| FY2011 | Dec 31, 2011 | 0 | Sep 7, 2012 |
| FY2011 | Dec 31, 2010 | 0 | Sep 7, 2012 |
| FY2011 | Dec 31, 2009 | 0 | Sep 7, 2012 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 138.68M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 5.90M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 4.44M | Mar 31, 2025 |
| FY2023 | May 1, 2023 | 2.50M | Mar 5, 2024 |
| FY2023 | Apr 30, 2023 | 37.40M | Mar 5, 2024 |
| FY2023 | Dec 31, 2022 | 2.24M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 15.51M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 6.75M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 3.88M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | 296,609 | Mar 30, 2020 |